title: Clinical results of microwave thermotherapy for benign prostatic hyperplasia.
abstract: Transurethral microwave thermotherapy is a truly office procedure without the need for anesthesia for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia. Several devices have been developed. Continuous refinement of the procedure led to higher energy protocols and high-intensity dose protocols applying the heat-shock strategy. We report on the clinical results of these protocols. Symptom scores improve around 60%, whereas maximum urinary flow rate improve from an average 9 to 10 mL/sec at baseline to 14 to 15 mL/sec during follow-up. No significant differences have been shown between the outcomes with the different devices. Long-term data show satisfactory results after 4 years. Initial clinical results with the heat-shock strategy show results comparable to those of higher-energy protocols with decreased morbidity. Treatment morbidity of higher energy protocols is moderate and consists mainly of the need for catheterization and a higher percentage of retrograde ejaculation. To improve treatment efficacy, patient selection appears to be most important. Prostate size, bladder outlet obstruction, age, and prostate composition are of predictive value for treatment outcome. Further development of the treatment protocols and refinement of the urethral applicators might enhance outcome.
authors.affiliation: Department of Urology, University Medical Center St. Radboud, Nijmegen, The Netherlands. mdewildt@worldonline.nl
authors.forename: M J
authors.initials: MJ
authors.lastname: de Wildt
authors.forename: L
authors.initials: L
authors.lastname: Wagrell
authors.forename: T R
authors.initials: TR
authors.lastname: Larson
authors.forename: T
authors.initials: T
authors.lastname: Eliasson
mesh_terms: D007172:Erectile Dysfunction / Q000209:etiology; D006801:Humans; D006979:Hyperthermia, Induced / Q000009:adverse effects / Q000379:methods* / Q000592:standards*; D008297:Male; D008872:Microwaves / Q000009:adverse effects / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000628:therapy*; D016896:Treatment Outcome; D016055:Urinary Retention / Q000209:etiology